Lori J. Wirth, MD

Articles

Dr Wirth on the Safety of Selpercatinib in RET Fusion+ Thyroid Cancer

July 25th 2024

Lori Wirth, MD, discusses the safety selpercatinib in adult or pediatric patients with advanced or metastatic RET fusion–positive thyroid cancer.

Dr Wirth on Questions About Selpercatinib Use in Advanced RET Fusion+ Thyroid Cancer

July 11th 2024

Lori Wirth, MD, discusses questions about the treatment of patients with RET fusion+ thyroid cancer following the full approval of selpercatinib.

Dr Wirth on the LIBRETTO-001 Trial of Selpercatinib in RET Fusion+ Thyroid Cancer

July 3rd 2024

Lori Wirth, MD, discusses the LIBRETTO-001 trial of selpercatinib for patients with advanced or metastatic RET fusion–positive thyroid cancer.

Dr Wirth on the Full FDA Approval of Selpercatinib for Advanced RET Fusion+ Thyroid Cancer

June 28th 2024

Lori Wirth, MD, discusses the significance of the full FDA approval of selpercatinib for patients with advanced or metastatic RET fusion+ thyroid cancer.

Exploring Real-World Evidence Presented at ATA 2023

April 26th 2024

Medical professionals discuss the recently published real-world evidence presented at the American Thyroid Association 2023 Conference.

Determining Which DTC Patients May Benefit from Systemic Therapy

April 26th 2024

Hyunseok Kang, MD, discusses the importance of balancing toxicities and other factors when initiating first-line treatments for patients with refractory differentiated thyroid cancer (DTC), while emphasizing the need to set clear goals and communicate potential adverse reactions before allowing patients to make informed decisions.

Differentiated Thyroid Cancer: Unmet Needs and Future Directions

May 20th 2022

Experts highlight remaining unmet needs in the management of radioiodine-refractory differentiated thyroid cancer and share their hopes for the future.

Practical Advice for Community Endocrinologists and Oncologists Treating DTC

May 13th 2022

Before closing out their discussion on radioiodine-refractory DTC management, experts share practical advice for community physicians.

Patient Surveillance and Therapy Selection in RAIR DTC

May 13th 2022

Shared insight on active surveillance practices for patients with radioiodine-refractory DTC and how disease factors play into selection of therapy at time of recurrence.

Defining RAI-Refractory DTC and Selecting Patients for Disease Monitoring

May 6th 2022

Reflecting on a real-world patient scenario of DTC, experts consider how they identify radioiodine-refractory disease and when they would initiate systemic therapy.

Patient Profile 2: Diagnosing and Assessing DTC

May 6th 2022

Expert Lori Wirth, MD, highlights key points from a second real-world patient scenario of radioiodine-refractory differentiated thyroid cancer.

Treatment of DTC With Lenvatinib: Managing Adverse Events

April 29th 2022

Expert advice on addressing adverse events, particularly through dose holds or reduction, in patients on lenvatinib therapy for radioiodine-refractory DTC.

Optimizing the Use of Lenvatinib in DTC: Patient Selection and Dosing

April 29th 2022

Shared insight on selecting appropriate patients for lenvatinib therapy in differentiated thyroid cancer, as well as optimizing dosing strategies in the context of clinical trial data.

Role of Endocrinologists and Oncologists in the Management of DTC

April 22nd 2022

A brief discussion on where endocrinologists and oncologists respectively fit into the differentiated thyroid cancer treatment paradigm.

Factors in Selecting Treatment for DTC

April 22nd 2022

Reflecting on the first patient scenario of radioiodine-refractory DTC, experts share their considerations for optimally selecting and sequencing therapy in this setting.

Patient Profile 1: Lenvatinib in the Treatment of RAI-Refractory DTC

April 15th 2022

Perspectives on the use of lenvatinib therapy to manage a patient with radioiodine-refractory DTC, preceding broader considerations for sequencing kinase inhibitor therapy.

Patient Profile 1: Radioiodine-Refractory Differentiated Thyroid Cancer

April 15th 2022

Expert Marcia Brose, MD, details a clinical scenario wherein a patient is diagnosed with differentiated thyroid cancer and managed with surgical and radiotherapy.

Novel Treatment Advances in Differentiated Thyroid Cancer

February 3rd 2022

An overview of therapies in the pipeline for differentiated thyroid cancer and their potential effect on clinical decision-making.

Second-Line Treatment Approaches for DTC

February 3rd 2022

Naifa L. Busaidy, MD, FACP, FACE, recognizes the importance of reassessing patients prior to considering a second-line therapy for differentiated thyroid cancer.

BRAF Inhibitors and Immunotherapy for Differentiated Thyroid Cancer

February 3rd 2022

The role of BRAF inhibitors and checkpoint inhibitors in differentiated thyroid cancer, and potential considerations for using BRAF inhibition as redifferentiation therapy.